Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients With Chronic Treatment-resistant Depression: A 12-Week Case Series
Authors:
- Maria PepeMPMaria Pepe
- Giovanni BartolucciGBGiovanni Bartolucci
- Ilaria MarcelliIMIlaria Marcelli
- Alessio SimonettiASAlessio Simonetti
- Giovanni CamardeseGCGiovanni Camardese
- Marco Di NicolaMNMarco Di Nicola
- Gabriele SaniGSGabriele Sani
- 1 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 29 (4) , 325-332
Abstract
Background: Cognitive symptoms are a core feature of depressive disorders, interfere with full functional recovery and are prominent in patients with treatment-resistant depression (TRD), particularly in severe chronic cases. Intranasal (IN) esketamine was recently approved for the treatment of TRD; however, its effects on cognitive symptoms are unclear. In this article, we describe cognitive changes in 8 patients with chronic TRD who were treated with IN administration of esketamine. Methods: Eight outpatients with chronic TRD received IN esketamine over 3 months and were assessed at baseline and after 4, 8, and 12 weeks of treatment using the Montgomery-Åsberg Depression Rating Scale (MADRS), the Digit Symbol Substitution Test (DSST), the Trail Making Test-B (TMT-B), the Patient Deficits Questionnaire for Depression 5-item (PDQ-D5), the Hamilton Anxiety Rating Scale (HARS), and the Clinical Global Impressions Scale (CGI). Findings: We observed reductions in cognitive symptoms according to DSST, TMT-B, and PDQ-D5 scores within the first 2 months of treatment with IN esketamine. These improvements were observed before patients achieved clinical response (≥50% decrease in baseline MADRS scores), and they also occurred earlier than reductions in HARS scores. Conclusions: A clinical response to IN esketamine was detected in severely ill patients with chronic TRD after 3 months of treatment. Interestingly, improvements on measures of cognitive symptoms were observed before patients achieved antidepressant response. These preliminary observations suggest an additional value to the antidepressant properties of IN esketamine. Clinical studies specifically investigating cognition as a primary outcome measure of IN esketamine in TRD are warranted.Keywords
This publication has 37 references indexed in Scilit:
- The Trail Making TestAssessment, 2016
- The Perceived Deficits QuestionnaireInternational Journal of MS Care, 2016
- Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approachJournal of Affective Disorders, 2014
- Cognitive impairment in depression: a systematic review and meta-analysisPsychological Medicine, 2013
- Ketamine for Treatment-Resistant Unipolar DepressionCNS Drugs, 2012
- Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorderDepression and Anxiety, 2009
- Psychometric Characteristics and Practice Effects of the Brunswick Trail Making TestPerceptual and Motor Skills, 2008
- Evidence of practice effects in variants of the Trail Making Test during serial assessmentJournal of Clinical and Experimental Neuropsychology, 2008
- Untreated Depression and Hippocampal Volume LossAmerican Journal of Psychiatry, 2003
- NMDA Antagonist Neurotoxicity: Mechanism and PreventionScience, 1991